首页> 外文期刊>Molecular cancer research: MCR >Targeting RNA Polymerase I with Hernandonine Inhibits Ribosomal RNA Synthesis and Tumor Cell Growth
【24h】

Targeting RNA Polymerase I with Hernandonine Inhibits Ribosomal RNA Synthesis and Tumor Cell Growth

机译:靶向RNA聚合酶I与Hernandonine抑制核糖体RNA合成和肿瘤细胞生长

获取原文
获取原文并翻译 | 示例
           

摘要

RNA polymerase I (RNA Pol. I) activity is consistently expanded in multiplying cells to continue the expanded interest for ribosome generation and protein synthesis, which are fundamental for cell development and division. Thus, selective inhibitors of RNA Pol. I may offer a general helpful intends to block cancer cell multiplication. Hernandonine, isolated from the root wood of Hernandia nymphaeifolia , causes rearrangement of nucleolar proteins consistent with segregation of the nucleolus, a hallmark of RNA Pol. I transcription stress. Furthermore, the compound destabilizes RPA194, the large catalytic protein of RNA Pol. I, in a proteasome-dependent manner and inhibits nascent rRNA synthesis and expression of the 45S rRNA precursor. Finally, hernandonine induces cellular apoptosis through a p53-dependent or p53-independent process in solid tumor cell lines. These outcomes feature the prevailing effect of RNA Pol. I transcription stress on apoptosis pathway initiation and present a synthetically novel and significant molecule that represses RNA Pol. I, making it a potential objective for malignancy treatment. Implications: Our findings position hernandonine as a potential, particular, and orally administered cancer treatment agent appropriate for use in investigational clinical trials.
机译:RNA聚合酶I(RNA pol.I)活性在繁殖细胞中始终扩增,以继续对核糖体产生和蛋白质合成的扩大兴趣,这是细胞开发和划分的基础。因此,RNA Pol的选择性抑制剂。我可以提供一般有用的意图阻止癌细胞倍增。与Hernandia Nymphaeifolia的根木头隔离的Hernandonine导致核仁蛋白与核仁的偏析一致,RNA Pol的标志。我转录压力。此外,该复合使RPA194变得稳定,RNA Pol的大催化蛋白。 I,以蛋白酶体依赖性的方式,抑制新生的RRNA合成和45s RRNA前体的表达。最后,Hernandonine通过在实体肿瘤细胞系中的p53依赖性或p53依赖性方法诱导细胞凋亡。这些结果具有RNA Pol的普遍效应。 I转录对凋亡途径启动的胁迫,并呈​​现抑制RNA Pol的合成新颖和重要分子。我,使其成为恶性治疗的潜在目标。含义:我们的研究结果将Hernandonine定位为适合于调查临床试验的潜在,特别和口服癌症治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号